Pfizer Limited Market Cap ($1.80 Billion)
Market Cap & Net Worth: Pfizer Limited (PFIZER)
Pfizer Limited market cap. Pfizer Limited (NSE:PFIZER) has a market capitalization of $1.80 Billion (Rs166.46 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #6296 globally and #282 in its home market, demonstrating a 0.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pfizer Limited's stock price Rs3638.70 by its total outstanding shares 45747732 (45.75 Million). Also see Pfizer Limited (PFIZER) cash conversion ratio for how efficiently the company converts equity into cash flow.
Pfizer Limited Market Cap History (2015–2026)
Pfizer Limited market cap history from 2015 to 2026. Data shows growth from $1.01 Billion to $1.80 Billion (4.84% CAGR). Check PFIZER stock price for real-time trading data and today's change.
Index Memberships
Pfizer Limited is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$2.99 Trillion | 0.06% | #249 of 500 |
|
NIFTY DIVIDEND OPPORTUNITIES 50
NIFTYDVOP
|
$736.87 Billion | 0.24% | #35 of 49 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.08 Trillion | 0.17% | #160 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.08 Trillion | 0.06% | #244 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$385.24 Billion | 0.47% | #68 of 250 |
Weight: Pfizer Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pfizer Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pfizer Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Pfizer Limited to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.07x
Pfizer Limited's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.25x
Pfizer Limited's market cap is 0.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $908.14 Million | $19.66 Billion | $3.37 Billion | 0.05x | 0.27x |
| 2018 | $1.26 Billion | $19.69 Billion | $3.60 Billion | 0.06x | 0.35x |
| 2019 | $1.88 Billion | $20.82 Billion | $4.29 Billion | 0.09x | 0.44x |
| 2020 | $2.44 Billion | $21.52 Billion | $5.09 Billion | 0.11x | 0.48x |
| 2021 | $2.43 Billion | $22.40 Billion | $4.98 Billion | 0.11x | 0.49x |
| 2022 | $2.16 Billion | $26.11 Billion | $6.13 Billion | 0.08x | 0.35x |
| 2023 | $2.10 Billion | $24.25 Billion | $6.24 Billion | 0.09x | 0.34x |
| 2024 | $2.61 Billion | $21.93 Billion | $5.51 Billion | 0.12x | 0.47x |
| 2025 | $2.47 Billion | $22.81 Billion | $7.68 Billion | 0.11x | 0.32x |
| 2026 | $1.80 Billion | $25.20 Billion | $7.22 Billion | 0.07x | 0.25x |
Competitor Companies of PFIZER by Market Capitalization
Companies near Pfizer Limited in the global market cap rankings as of November 4, 2026. Also see Pfizer Limited assets under control for a full breakdown of the balance sheet.
Key companies related to Pfizer Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.84 |
Market Capitalization of Pfizer Limited (2015–2026)
Market capitalization of Pfizer Limited from 2015 to today. Between 2015 and today, Pfizer Limited's market cap moved from $1.01 Billion to $ 1.80 Billion, with a yearly change of 4.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.80 Billion | -27.05% |
| 2025 | Rs2.47 Billion | -5.56% |
| 2024 | Rs2.61 Billion | +24.46% |
| 2023 | Rs2.10 Billion | -2.83% |
| 2022 | Rs2.16 Billion | -10.97% |
| 2021 | Rs2.43 Billion | -0.50% |
| 2020 | Rs2.44 Billion | +29.47% |
| 2019 | Rs1.88 Billion | +49.11% |
| 2018 | Rs1.26 Billion | +39.11% |
| 2017 | Rs908.14 Million | +15.38% |
| 2016 | Rs787.11 Million | -22.04% |
| 2015 | Rs1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Pfizer Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterolog… Read more